Metergoline Abolishes the Prolactin Response to Buspirone

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1990 Jan 1

PMID 2305017

Citations 4

Authors

C A Gregory

I M Anderson

P J Cowen

Affiliations

Soon will be listed here.

Abstract

Pretreatment of nine healthy subjects with the non-selective 5-HT receptor antagonist, metergoline (4 mg), abolished the increase in plasma prolactin produced by the anxiolytic drug, buspirone (15 mg). While these findings are consistent with a role for 5-HT receptors in the stimulatory effect of buspirone on plasma prolactin, a dopaminergic mechanism cannot be excluded by the present data.

Citing Articles

Corticosteroid-serotonin interactions in depression: a review of the human evidence.

Porter R, Gallagher P, Watson S, Young A Psychopharmacology (Berl). 2004; 173(1-2):1-17.

PMID: 15007595 DOI: 10.1007/s00213-004-1774-1.

Does metergoline selectively attenuate 5-HT mediated prolactin release?.

Ellis P, Gartside S, Ware C, Campling G, Cowen P Psychopharmacology (Berl). 1991; 105(1):129-31.

PMID: 1745704 DOI: 10.1007/BF02316875.

Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome.

Bakheit A, Behan P, Dinan T, GRAY C, OKeane V BMJ. 1992; 304(6833):1010-2.

PMID: 1586780 PMC: 1881733. DOI: 10.1136/bmj.304.6833.1010.

Effect of pindolol on endocrine and temperature responses to buspirone in healthy volunteers.

Anderson I, Cowen P Psychopharmacology (Berl). 1992; 106(3):428-32.

PMID: 1570392 DOI: 10.1007/BF02245430.

References

Mueller E, Murphy D, Sunderland T . Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans. Psychopharmacology (Berl). 1986; 89(3):388-91. DOI: 10.1007/BF00174380. View

KRULICH L, McCANN S, Mayfield M . On the mode of the prolactin release-inhibiting action of the serotonin receptor blockers metergoline, methysergide, and cyproheptadine. Endocrinology. 1981; 108(4):1115-24. DOI: 10.1210/endo-108-4-1115. View

Eison A, Temple Jr D . Buspirone: review of its pharmacology and current perspectives on its mechanism of action. Am J Med. 1986; 80(3B):1-9. DOI: 10.1016/0002-9343(86)90325-6. View

Muller E, Locatelli V, Cella S, Penalva A, Novelli A, Cocchi D . Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications. Drugs. 1983; 25(4):399-432. DOI: 10.2165/00003495-198325040-00004. View

McMILLEN B, Matthews R, Sanghera M, Shepard P, German D . Dopamine receptor antagonism by the novel antianxiety drug, buspirone. J Neurosci. 1983; 3(4):733-8. PMC: 6564456. View

Meltzer H, Flemming R, Robertson A . The effect of buspirone on prolactin and growth hormone secretion in man. Arch Gen Psychiatry. 1983; 40(10):1099-102. DOI: 10.1001/archpsyc.1983.01790090061009. View

Ferrari C, Caldara R, ROMUSSI M, Rampini P, Telloli P, Zaatar S . Prolactin suppression by serotonin antagonists in man: further evidence for serotoninergic control of prolactin secretion. Neuroendocrinology. 1978; 25(6):319-28. DOI: 10.1159/000122753. View

Fuxe K, Agnati L, Everitt B . Effects of methergoline on central monoamine neurones. Evidence for a selective blockade of central 5-HT receptors. Neurosci Lett. 2009; 1(5):283-90. DOI: 10.1016/0304-3940(75)90044-0. View

Meltzer H, Simonovic M, Fang V, Gudelsky G . Effect of buspirone on rat plasma prolactin levels and striatal dopamine turnover. Psychopharmacology (Berl). 1982; 78(1):49-53. DOI: 10.1007/BF00470587. View

10.

Benkelfat C, Murphy D, Zohar J, Hill J, Grover G, Insel T . Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action. Arch Gen Psychiatry. 1989; 46(1):23-8. DOI: 10.1001/archpsyc.1989.01810010025004. View

11.

Griffith J, Jasinski D, CASTEN G, McKINNEY G . Investigation of the abuse liability of buspirone in alcohol-dependent patients. Am J Med. 1986; 80(3B):30-5. DOI: 10.1016/0002-9343(86)90329-3. View

12.

Seppala T, Ranta T, Shrotriya R . Serum prolactin levels after buspirone in man. Med Biol. 1987; 65(1):61-3. View

13.

Martin L, Sanders-Bush E . Comparison of the pharmacological characteristics of 5 HT1 and 5 HT2 binding sites with those of serotonin autoreceptors which modulate serotonin release. Naunyn Schmiedebergs Arch Pharmacol. 1982; 321(3):165-70. DOI: 10.1007/BF00505480. View